Mostrando 10 resultados de: 17
Filtros aplicados
Publisher
Pharmacogenomics Journal(5)
European Journal of Clinical Pharmacology(3)
Pharmacogenomics(2)
European Journal of Drug Metabolism and Pharmacokinetics(1)
Expert Opinion on Drug Metabolism and Toxicology(1)
CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards
ArticleAbstract: Earlier we had found that the CYP2C9*2 allelic frequency was lower in Mexican-Americans living in CaPalabras claves:CYP2C9, Hispanics, Mexican-Americans, Mexican-Mestizos, Mexican-Tepehuanos, pharmacogeneticsAutores:Adrián LLerena, Alanis-Bãuelos R.E., Dorado P., Lares-Asseff I., Licinio J., Penãs-Lledó E.M., Sosa-Macías M.G., Wong M.L.Fuentes:scopusCYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers
ArticleAbstract: Objective: This study analyzed the frequency of CYP2C9 variant alleles and evaluated the impact of CPalabras claves:CYP2C9, Diclofenac, GenotypingAutores:Adrián LLerena, Berecz R., Dahl M.L., Dorado P., Norberto M., Yasar U.Fuentes:scopusGenetic variability of CYP2C9∗2 and CYP2C9∗3 in seven indigenous groups from Mexico
ArticleAbstract: Aim: CYP2C9 is one of the major drug metabolizing enzymes, however, little is known about polymorphiPalabras claves:allele frequency, CYP2C9, hypoglycemic therapy, Mexican indigenous, pharmacogenetics, polymorphismAutores:Adrián LLerena, García-Rodríguez M., Granados-Silvestre M., Menjívar M., Ortiz-López M.G., Peña-Espinoza B., Rivera-Santiago C., Sánchez-Pozos K.Fuentes:scopusEffect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions
ArticleAbstract: Objectives: CYP2D6 drug-metabolising enzyme has been shown to be involved in fluoxetine metabolism iPalabras claves:CYP2C9, CYP2D6, Selective serotonin reuptake inhibitorsAutores:Adrián LLerena, Berecz R., Dorado P., González A.P., Penãs-Lledó E.M.Fuentes:scopusNeurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: Influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms
ArticleAbstract: Pharmacogenetic studies have shown that genetic defects in drug-metabolizing enzymes encoded by CYP2Palabras claves:CYP2C19, CYP2C9, Epilepsy, Neurological toxicity, paediatric, PhenytoinAutores:Adrián LLerena, Dorado P., López-Torres E., Martínez-Antón J., Penãs-Lledó E.M.Fuentes:scopusIncreased risk for major depression associated with the short allele of the serotonin transporter promoter region (5-HTTLPR-S) and the CYP2C9*3 allele
Conference ObjectAbstract: In the present study, we aimed to analyze the potential relevance of the polymorphism in the promotePalabras claves:5-HTTLPR, CYP2C9, genetic polymorphism, major depression, SerotoninAutores:Adrián LLerena, Cáceres M.C., Cobaleda J., Dorado P., González A.P., Penãs-Lledó E.M.Fuentes:scopusInfluence of admixture components on CYP2C9*2 allele frequency in eight indigenous populations from Northwest Mexico
ArticleAbstract: We previously documented the lowest frequency of CYP2C9*2 in Mexican indigenous Tepehuanos followedPalabras claves:ancestral components, CYP2C9, Mexican indigenous, pharmacogeneticsAutores:Adrián LLerena, Dorado P., Galaviz-Hernandez C., Lazalde-Ramos B.P., Licinio J., Martínez-Fierro M.L., Martínez-Sevilla V.M., Rangel-Villalobos H., Salazar-Flores J., Sosa-Macías M.G., Wong M.L.Fuentes:scopusLower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards
ArticleAbstract: Interethnic differences in cytochrome P450 polymorphism might be responsible, at least in part, forPalabras claves:CYP2C9, Hispanics, Mexican-Americans, pharmacogenetics, SpaniardsAutores:Adrián LLerena, Dorado P., Jepson R., Licinio J., O'Kirwan F., Wong M.L.Fuentes:scopusInterethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain
ArticleAbstract: The aims of this study were to evaluate the diclofenac metabolism in Hispanics from Cuba and Spain aPalabras claves:CYP2C9, Diclofenac, Environmental factors, Genotype, Hispanics, PhenotypeAutores:Adrián LLerena, Alvárez M., Calzadilla L.R., Cobaleda J., Dorado P., González I., Penãs-Lledó E.M., Pérez B.Fuentes:scopusInterethnic variability in CYP2D6, CYP2C9, and CYP2C19 genes and pbkp_redicted drug metabolism phenotypes among 6060 ibero-and native Americans: RIBEF-CEIBA consortium report on population pharmacogenomics
ArticleAbstract: Pharmacogenetic variation in Latin Americans is understudied, which sets a barrier for the goal of gPalabras claves:Amerindians, CYP2C19, CYP2C9, CYP2D6, drug metabolism, LATIN AMERICANS, pharmacogenetics, Precision MedicineAutores:Adrián LLerena, Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Fcrreiro V., Francisco J.López Hernández, Fricke-Galindo I., Galaviz-Hernandez C., Garza-Ocañas L., Gilman R.H., Gouveia M.H., Grazina M., Humberto Fariñas, Jiménez-Arce G., Jung-Cook H., Lares-Aseff I., Lazalde-Ramos B.P., López-López M., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rodrigues-Soares F., Rojas-Martinez A., Santiago Terán, Sarmiento A.P., Scliar M.O., Sosa-Macías M.G., Tarazona-Santos E.M., Tinoco C.A., Zamudio R.Fuentes:googlescopus